{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:29:32Z","timestamp":1793276972377,"version":"4.5.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.cld.2023.05.010","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T15:35:04Z","timestamp":1688225704000},"page":"955-972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Triple Threat: HDV, HBV, HIV Coinfection"],"prefix":"10.1016","volume":"27","author":[{"given":"Debra W.","family":"Yen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Barreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.cld.2023.05.010_bib1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/QAD.0000000000001424","article-title":"Hepatitis delta and HIV infection","volume":"31","author":"Soriano","year":"2017","journal-title":"AIDS (Lond)"},{"issue":"3","key":"10.1016\/j.cld.2023.05.010_bib2","first-page":"203","article-title":"German advisory committee blood (arbeitskreis blut), subgroup \u2018assessment of pathogens transmissible by blood\u2019. Human immunodeficiency virus (HIV)","volume":"43","year":"2016","journal-title":"Transfus Med Hemother"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.28013","article-title":"A\u00a0targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses","volume":"63","author":"Verrier","year":"2016","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2023.05.010_bib4","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","article-title":"Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease","volume":"70","author":"Urban","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cld.2023.05.010_bib5","doi-asserted-by":"crossref","first-page":"104812","DOI":"10.1016\/j.antiviral.2020.104812","article-title":"Current knowledge on hepatitis delta virus replication","volume":"179","author":"Lucifora","year":"2020","journal-title":"Antivir Res"},{"issue":"2","key":"10.1016\/j.cld.2023.05.010_bib6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/v14020198","article-title":"Adaptive immune responses, immune escape and immune-mediated pathogenesis during HDV infection","volume":"14","author":"Oberhardt","year":"2022","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib7","doi-asserted-by":"crossref","first-page":"e718","DOI":"10.1016\/S0618-8278(19)31437-9","article-title":"SAT-202-Endogenous and exogenous IFN responses suppress HDV persistence during proliferation of hepatocytes in\u00a0vitro","volume":"70","author":"Zhang","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.010_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.antiviral.2016.10.006","article-title":"HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes","volume":"136","author":"Alfaiate","year":"2016","journal-title":"Antivir Res"},{"issue":"4","key":"10.1016\/j.cld.2023.05.010_bib9","first-page":"100060","article-title":"Hepatitis delta virus acts as an immunogenic adjuvant in hepatitis B virus-infected hepatocytes. Cell reports","volume":"1","author":"Tham","year":"2020","journal-title":"Medicine"},{"issue":"11","key":"10.1016\/j.cld.2023.05.010_bib10","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3390\/v12111334","article-title":"Interplay between hepatitis D virus and the interferon response","volume":"12","author":"Zhang","year":"2020","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000282076","article-title":"Hepatitis delta: immunopathogenesis and clinical challenges","volume":"28","author":"Grabowski","year":"2010","journal-title":"Dig Dis"},{"issue":"9","key":"10.1016\/j.cld.2023.05.010_bib12","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1478-3231.2011.02593.x","article-title":"Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment","volume":"31","author":"Grabowski","year":"2011","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.cld.2023.05.010_bib13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/infdis\/jiy549","article-title":"Detection of a broad range of low-level major histocompatibility complex class II\u2013restricted, hepatitis delta virus (HDV)\u2013Specific T-cell responses regardless of clinical status","volume":"219","author":"Landahl","year":"2019","journal-title":"J\u00a0Infect Dis"},{"issue":"6","key":"10.1016\/j.cld.2023.05.010_bib14","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2019.01.035","article-title":"Hepatitis D virus-specific CD8+ T\u00a0cells have a memory-like phenotype associated with viral immune escape in patients with chronic hepatitis D virus infection","volume":"156","author":"Kefalakes","year":"2019","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2023.05.010_bib15","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1053\/j.gastro.2019.02.003","article-title":"Mutations in hepatitis D virus allow it to escape detection by CD8+ T\u00a0cells and evolve at the population level","volume":"156","author":"Karimzadeh","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2023.05.010_bib16","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1478-3231.2009.02140.x","article-title":"Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis","volume":"30","author":"Zachou","year":"2010","journal-title":"Liver Int"},{"issue":"13","key":"10.1016\/j.cld.2023.05.010_bib17","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/01.aids.0000180787.10553.b2","article-title":"Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain","volume":"19","author":"Arribas","year":"2005","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2893.2000.00195.x","article-title":"Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections","volume":"7","author":"Mathurin","year":"2000","journal-title":"J\u00a0Viral Hepat"},{"issue":"2","key":"10.1016\/j.cld.2023.05.010_bib19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1053\/jhep.2001.26511","article-title":"Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference","volume":"34","author":"Jardi","year":"2001","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2893.2009.01153.x","article-title":"Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus","volume":"17","author":"Boyd","year":"2010","journal-title":"J\u00a0Viral Hepat"},{"issue":"Pt 11","key":"10.1016\/j.cld.2023.05.010_bib21","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1099\/vir.0.011239-0","article-title":"Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha\/beta interferon-inducible MxA gene","volume":"90","author":"Williams","year":"2009","journal-title":"J\u00a0Gen Virol"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1128\/JVI.01609-10","article-title":"Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses","volume":"85","author":"Pollicino","year":"2011","journal-title":"J\u00a0Virol"},{"issue":"6","key":"10.1016\/j.cld.2023.05.010_bib23","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/infdis\/163.6.1351","article-title":"Influence of human immunodeficiency virus infection on cell-mediated immunity in chronic D hepatitis","volume":"163","author":"Buti","year":"1991","journal-title":"J\u00a0Infect Dis"},{"issue":"2","key":"10.1016\/j.cld.2023.05.010_bib24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2893.1994.tb00112.x","article-title":"Influence of human immunodeficiency virus infection on hepatitis \u03b4 virus superinfection in chronic HBsAg carriers","volume":"1","author":"Pol","year":"1994","journal-title":"J\u00a0Viral Hepat"},{"issue":"3","key":"10.1016\/j.cld.2023.05.010_bib25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/jmv.1890380307","article-title":"Persistent delta antigenaemia in chronic delta hepatitis and its relation with human immunodeficiency virus infection","volume":"38","author":"Roingeard","year":"1992","journal-title":"J\u00a0Med Virol"},{"issue":"6","key":"10.1016\/j.cld.2023.05.010_bib26","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3201\/eid2706.210284","article-title":"Reflections on 40 Years of AIDS","volume":"27","author":"DeCock","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cld.2023.05.010_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.13797","article-title":"Delta hepatitis epidemiology and the global burden of disease","author":"Kushner","year":"2023","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2023.05.010_bib28","series-title":"Global hepatitis report","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.cld.2023.05.010_bib29","series-title":"Global health sector strategy on viral hepatitis 2016-2021","author":"World Health Organization","year":"2016"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13690-021-00693-2","article-title":"The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?","volume":"79","author":"Hayashi","year":"2021","journal-title":"Arch Publ Health"},{"issue":"9","key":"10.1016\/j.cld.2023.05.010_bib31","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"7","author":"Ippolito","year":"2022","journal-title":"The lancet. Gastroenterology & hepatology"},{"issue":"5","key":"10.1016\/j.cld.2023.05.010_bib32","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"7","author":"Tacke","year":"2022","journal-title":"The lancet. Gastroenterology & hepatology"},{"key":"10.1016\/j.cld.2023.05.010_bib33","unstructured":"UNAIDS. HIV\/AIDS report 2022."},{"issue":"3","key":"10.1016\/j.cld.2023.05.010_bib34","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","volume":"68","author":"Chen","year":"2019","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cld.2023.05.010_bib35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2023.05.010_bib36","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jhep.2020.05.019","article-title":"Revisiting the estimation of hepatitis D global prevalence","volume":"73","author":"Miao","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2023.05.010_bib37","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/gutjnl-2018-317403","article-title":"Devil hepatitis D: an orphan disease or largely underdiagnosed?","volume":"68","author":"Wedemeyer","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.cld.2023.05.010_bib38","unstructured":"Centers for Disease Control and Prevention. US Public Health Service: pre-exposure prophylaxis for the prevention of HIV infection in the United States\u20142021 update: a clinical practice guideline."},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society\u2013USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA, J Am Med Assoc"},{"issue":"4","key":"10.1016\/j.cld.2023.05.010_bib40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11904-020-00508-z","article-title":"Epidee","volume":"17","author":"Ferrante","year":"2020","journal-title":"Curr HIV AIDS Rep"},{"key":"10.1016\/j.cld.2023.05.010_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/liv.15519","article-title":"Hepatitis delta infection among persons living with HIV in Europe","author":"Beguelin","year":"2023","journal-title":"Liver Int"},{"issue":"16","key":"10.1016\/j.cld.2023.05.010_bib42","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1097\/QAD.0b013e32834babb3","article-title":"Hepatitis delta in HIV-infected individuals in Europe","volume":"25","author":"Soriano","year":"2011","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.cld.2023.05.010_bib43","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","article-title":"Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis","volume":"16","author":"Platt","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.cld.2023.05.010_bib44","doi-asserted-by":"crossref","first-page":"e0269250","DOI":"10.1371\/journal.pone.0269250","article-title":"Epidemiology of hepatitis B virus and\/or hepatitis C virus infections among people living with human immunodeficiency virus in Africa: a systematic review and meta-analysis","volume":"17","author":"Kenfack-Momo","year":"2022","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.cld.2023.05.010_bib45","doi-asserted-by":"crossref","first-page":"e37016","DOI":"10.2196\/37016","article-title":"Underestimated prevalence of HIV, hepatitis B virus (HBV), and hepatitis D virus (HDV) triple infection globally: systematic review and meta-analysis","volume":"8","author":"Chen","year":"2022","journal-title":"JMIR public health and surveillance"},{"issue":"5","key":"10.1016\/j.cld.2023.05.010_bib46","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1089\/aid.2007.0240","article-title":"Profile of patients triply infected with HIV and the hepatitis B and C viruses in the HAART era","volume":"24","author":"Maida","year":"2008","journal-title":"AIDS Res Hum Retrovir"},{"issue":"9","key":"10.1016\/j.cld.2023.05.010_bib47","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3201\/eid1209.060112","article-title":"Eighth major clade for hepatitis delta virus","volume":"12","author":"Le Gal","year":"2006","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib48","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jcv.2014.05.021","article-title":"Molecular epidemiology of hepatitis delta virus in the Western Pacific region","volume":"61","author":"Han","year":"2014","journal-title":"J\u00a0Clin Virol"},{"issue":"5","key":"10.1016\/j.cld.2023.05.010_bib49","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/JCM.02297-13","article-title":"Characterization of hepatitis delta virus in sub-saharan Africa","volume":"52","author":"Andernach","year":"2014","journal-title":"J\u00a0Clin Microbiol"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3851\/IMP3161","article-title":"Decline and changing profile of hepatitis delta among injection drug users in Spain","volume":"23","author":"Aguilera","year":"2018","journal-title":"Antivir Ther"},{"issue":"5","key":"10.1016\/j.cld.2023.05.010_bib51","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1053\/j.gastro.2009.01.052","article-title":"A\u00a028-year study of the course of hepatitis \u0394 infection: a risk factor for cirrhosis and hepatocellular carcinoma","volume":"136","author":"Romeo","year":"2009","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2023.05.010_bib52","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.46.3.420","article-title":"Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B","volume":"46","author":"Fattovich","year":"2000","journal-title":"Gut"},{"issue":"14","key":"10.1016\/j.cld.2023.05.010_bib53","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1097\/QAD.0000000000003024","article-title":"Hepatitis delta in patients hospitalized in Spain (1997\u20132018)","volume":"35","author":"Ramos-Rincon","year":"2021","journal-title":"AIDS (Lond)"},{"key":"10.1016\/j.cld.2023.05.010_bib54","article-title":"Natural history of untreated HDV patients: always a progressive disease?","author":"Kamal","year":"2022","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.cld.2023.05.010_bib55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2893.2007.00903.x","article-title":"Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome","volume":"15","author":"Castellares","year":"2008","journal-title":"J\u00a0Viral Hepat"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib56","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jmii.2013.08.001","article-title":"Higher rate of hepatitis events in patients with human immunodeficiency virus, hepatitis B, and hepatitis D genotype II infection: a cohort study in a medical center in southern Taiwan","volume":"48","author":"Lee","year":"2013","journal-title":"J\u00a0Microbiol Immunol Infect"},{"issue":"7","key":"10.1016\/j.cld.2023.05.010_bib57","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1086\/511867","article-title":"Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study","volume":"44","author":"Sheng","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cld.2023.05.010_bib58","unstructured":"European AIDS Clinical Society (EACS) Guidelines version 11.1. 2022."},{"issue":"3","key":"10.1016\/j.cld.2023.05.010_bib59","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2020.02.030","article-title":"Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies","volume":"73","author":"Alfaiate","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib60","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1038\/s41467-020-18186-1","article-title":"The genomic landscape of Mongolian hepatocellular carcinoma","volume":"11","author":"Candia","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib61","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1186\/s12879-016-1992-2","article-title":"A\u00a0prominent role of Hepatitis D Virus in liver cancers documented in Central Africa","volume":"16","author":"Amougou","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib62","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9270(00)02167-5","article-title":"Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C","volume":"96","author":"Garc\u0131a-Samaniego","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"17","key":"10.1016\/j.cld.2023.05.010_bib63","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/00002030-200411190-00009","article-title":"Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome","volume":"18","author":"Puoti","year":"2004","journal-title":"AIDS"},{"issue":"Supplement 1","key":"10.1016\/j.cld.2023.05.010_bib64","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jhep.2005.11.029","article-title":"Management of hepatocellular carcinoma in HIV- infected patients","volume":"44","author":"Bruno","year":"2006","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2023.05.010_bib65","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jhep.2007.06.010","article-title":"Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.\u2013Canadian multicenter study","volume":"47","author":"Br\u00e4u","year":"2007","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2023.05.010_bib66","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/cid\/ciu167","article-title":"Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients","volume":"58","author":"Fern\u00e1ndez-Montero","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.cld.2023.05.010_bib67","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jhep.2016.10.007","article-title":"Hepatitis delta-associated mortality in HIV\/HBV-coinfected patients","volume":"66","author":"B\u00e9guelin","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2023.05.010_bib68","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/jnci\/djz214","article-title":"HIV RNA, CD4+ percentage, and risk of hepatocellular carcinoma by cirrhosis status","volume":"112","author":"Torgersen","year":"2020","journal-title":"JNCI : J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.cld.2023.05.010_bib69","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"4","key":"10.1016\/j.cld.2023.05.010_bib71","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"8531","key":"10.1016\/j.cld.2023.05.010_bib72","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(87)92090-3","article-title":"Serological response to hepatitis delta virus in hepatitis D","volume":"329","author":"Aragona","year":"1987","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.cld.2023.05.010_bib73","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/jama.1986.03370110065022","article-title":"Diagnostic and prognostic significance of the IgM antibody to the hepatitis delta virus","volume":"255","author":"Farci","year":"1986","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.cld.2023.05.010_bib74","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3851\/IMP1926","article-title":"Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-\u03b12a treatment","volume":"17","author":"Mederacke","year":"2012","journal-title":"Antivir Ther"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13099-020-00395-0","article-title":"Hepatitis D: challenges in the estimation of true prevalence and laboratory diagnosis","volume":"13","author":"Chen","year":"2021","journal-title":"Gut Pathog"},{"issue":"5","key":"10.1016\/j.cld.2023.05.010_bib76","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jhep.2009.10.036","article-title":"Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D","volume":"52","author":"Schaper","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2023.05.010_bib77","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1128\/JCM.02027-16","article-title":"Performance characteristics of a new consensus commercial kit for hepatitis D virus RNA viral load quantification","volume":"55","author":"LeGal","year":"2017","journal-title":"J\u00a0Clin Microbiol"},{"issue":"12","key":"10.1016\/j.cld.2023.05.010_bib78","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.14309\/ajg.0000000000001947","article-title":"Low performance of hepatitis delta virus testing among 2 national cohorts of chronic hepatitis B patients in the United States","volume":"117","author":"Wong","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2023.05.010_bib79","article-title":"Treatment of hepatitis delta and HIV infection","author":"Soriano","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2023.05.010_bib80","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.virusres.2018.03.013","article-title":"Hepatitis D diagnostics:Utilization and testing in the United States","volume":"250","author":"Safaie","year":"2018","journal-title":"Virus Res"},{"key":"10.1016\/j.cld.2023.05.010_bib81","doi-asserted-by":"crossref","unstructured":"Brancaccio G, Shanyinde M, Puoti M, et\u00a0al. Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy. 2022.","DOI":"10.1080\/20477724.2022.2047551"},{"issue":"10","key":"10.1016\/j.cld.2023.05.010_bib82","doi-asserted-by":"crossref","first-page":"100547","DOI":"10.1016\/j.jhepr.2022.100547","article-title":"Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D","volume":"4","author":"Palom","year":"2022","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1016\/j.cld.2023.05.010_bib83","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/jvh.13660","article-title":"Global prevalence of occult hepatitis B: a systematic review and meta-analysis","volume":"29","author":"Ji","year":"2022","journal-title":"J\u00a0Viral Hepat"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib84","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jhep.2011.06.016","article-title":"Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation","volume":"56","author":"Mederacke","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib85","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/gutjnl-2017-314713","article-title":"Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in\u00a0vitro and in\u00a0vivo","volume":"68","author":"Giersch","year":"2019","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.cld.2023.05.010_bib86","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/MEG.0000000000001187","article-title":"Short article: hepatitis delta in patients with resolved hepatitis B virus infection","volume":"30","author":"Aguilera","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2023.05.010_bib87","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jcv.2012.04.014","article-title":"HDAg-L variants in covert hepatitis D and HBV occult infection among Amerindians of Argentina: new insights","volume":"54","author":"Delfino","year":"2012","journal-title":"J\u00a0Clin Virol"},{"issue":"5","key":"10.1016\/j.cld.2023.05.010_bib88","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/MEG.0000000000001362","article-title":"Hepatitis D virus infection in patients with hepatitis B virus occult infection","volume":"31","author":"Oubi\u00f1a","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2023.05.010_bib89","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1097\/MEG.0000000000001253","article-title":"Delta hepatitis in resolved hepatitis B","volume":"30","author":"Ponzetto","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"16","key":"10.1016\/j.cld.2023.05.010_bib90","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1097\/QAD.0000000000000417","article-title":"Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients","volume":"28","author":"Soriano","year":"2014","journal-title":"AIDS (Lond)"},{"issue":"12","key":"10.1016\/j.cld.2023.05.010_bib91","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1089\/aid.2013.0008","article-title":"Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV\u2013hepatitis B virus\u2013hepatitis D virus-infected patients","volume":"29","author":"Boyd","year":"2013","journal-title":"AIDS Res Hum Retrovir"},{"issue":"9","key":"10.1016\/j.cld.2023.05.010_bib92","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/cid\/cix125","article-title":"Impact of tenofovir on hepatitis delta virus replication in the Swiss human immunodeficiency virus cohort study","volume":"64","author":"B\u00e9guelin","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"13","key":"10.1016\/j.cld.2023.05.010_bib93","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2217\/fmb-2021-0177","article-title":"Envisioning a hepatitis delta cure with new antivirals","volume":"16","author":"Soriano","year":"2021","journal-title":"Future Microbiol"},{"issue":"6","key":"10.1016\/j.cld.2023.05.010_bib94","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1002\/hep.32082","article-title":"Endpoints and new options for treatment of chronic hepatitis D","volume":"74","author":"Lok","year":"2021","journal-title":"Hepatology (Baltimore, Md"},{"issue":"5","key":"10.1016\/j.cld.2023.05.010_bib95","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3851\/IMP2728","article-title":"Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience","volume":"19","author":"Abbas","year":"2014","journal-title":"Antivir Ther"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib96","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib97","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cld.2023.05.010_bib98","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0168-8278(20)30651-6","article-title":"48\u00a0weeks of high dose (10\u00a0mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV\/HDV co-infection","volume":"73","author":"Wedemeyer","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.010_bib99","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.dld.2022.01.047","article-title":"Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24-week interim data of the phase 3 MYR301 study","volume":"54","author":"Wedemeyer","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cld.2023.05.010_bib100","unstructured":"de Ledinghen V, Gervais A, Hilleret M, et\u00a0al. Bulevirtide\u00a0+\/- PEG-IFN in HIV\/HBV\/HDV Coinfected Patients in Real-Life Settings Abstract 589. Presented at: 30th Conference on Retroviruses and Opportunistic Infections. 2023."},{"issue":"4","key":"10.1016\/j.cld.2023.05.010_bib101","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2023.05.010_bib102","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.32259","article-title":"A\u00a0phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis","volume":"75","author":"Yurdaydin","year":"2022","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.cld.2023.05.010_bib103","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"lancet. Gastroenterology & hepatology"},{"issue":"2","key":"10.1016\/j.cld.2023.05.010_bib104","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep4.1633","article-title":"Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139-Ca and pegylated interferon therapy in chronic hepatitis B virus\/hepatitis delta virus coinfection","volume":"5","author":"Bazinet","year":"2021","journal-title":"Hepatology communications"},{"key":"10.1016\/j.cld.2023.05.010_bib105","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000309","article-title":"Treatment of chronic hepatitis d with peginterferon lambda - the phase 2 LIMT-1 clinical trial","author":"Etzion","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2023.05.010_bib106","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/17512433.2018.1453805","article-title":"Treatment and prevention of HIV infection with long-acting antiretrovirals","volume":"11","author":"Ben\u00edtez-Guti\u00e9rrez","year":"2018","journal-title":"Expet Rev Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.cld.2023.05.010_bib107","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/s-0032-1323630","article-title":"Liver transplantation in delta virus infection","volume":"32","author":"Roche","year":"2012","journal-title":"Semin Liver Dis"},{"issue":"6","key":"10.1016\/j.cld.2023.05.010_bib108","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.transproceed.2016.02.076","article-title":"Hepatitis B virus and hepatitis D virus recurrence in patients undergoing liver transplantation for hepatitis B virus and hepatitis B virus plus hepatitis D virus","volume":"48","author":"Adil","year":"2016","journal-title":"Transplant Proc"},{"issue":"7","key":"10.1016\/j.cld.2023.05.010_bib109","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.transproceed.2019.01.163","article-title":"Recurrence of hepatitis D virus in liver transplant recipients with hepatitis B and D virus\u2013related chronic liver disease","volume":"51","author":"Serin","year":"2019","journal-title":"Transplant Proc"},{"issue":"1","key":"10.1016\/j.cld.2023.05.010_bib110","doi-asserted-by":"crossref","first-page":"e1253","DOI":"10.1097\/TXD.0000000000001253","article-title":"Liver transplantation for hepatitis D virus in the United States: a UNOS study on outcomes in the meld era","volume":"8","author":"Kushner","year":"2022","journal-title":"Transplantation Direct"},{"issue":"5","key":"10.1016\/j.cld.2023.05.010_bib111","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/hep.27553","article-title":"Human immunodeficiency virus and liver transplantation: hepatitis C is the last hurdle","volume":"61","author":"Stock","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2023.05.010_bib112","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/j.1600-6143.2010.03070.x","article-title":"Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients","volume":"10","author":"Coffin","year":"2010","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.cld.2023.05.010_bib113","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/QAD.0b013e32832c2a37","article-title":"Long-term follow-up of liver transplanted HIV\/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity","volume":"23","author":"Tateo","year":"2009","journal-title":"AIDS"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:01:55Z","timestamp":1761069715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326123000703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":113,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1089326123000703"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2023.05.010","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple Threat: HDV, HBV, HIV Coinfection","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2023.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}